Healthcare
Medacta Group S.A.(MEDGF)
Live Price
Offline$83.91
+0.00% today
Window Change
+0.00%
Window
Jun 23, 2025 โ Apr 7, 2026
- Market Cap
- $1.67B
- Revenue Growth
- +16.5%
- EPS Growth
- +31.4%
- Dividend Yield
- 0.5%
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 199 bars ยท Jun 23, 2025 โ Apr 7, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Medacta Group S.A. (MEDGF) is a Healthcare stock with a market cap of $1.67B and listed on OTC. The stock last traded around $83.91 and up 0.0% across the available one-year price window (Jun 23, 2025 โ Apr 7, 2026). Baseline metrics include revenue growth of +16.5%, EPS growth of +31.4%, a dividend yield of 0.5%. What stands out right now is revenue +16.5%, EPS +31.4%, free cash flow +1119.0% with operating margin 16.9% and ROIC 11.9%. The dividend is present but secondary, with a yield around 0.5%. Valuation already assumes a fairly strong business story at P/E 32.5 and price/sales 4.5. Stock Foundry combines MEDGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+16.5% vs +7.6% peer median
Operating Margin
Below sector median
+16.9% vs +19.4% peer median
P/E
Below sector median
32.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Mar 23, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +16.5% and EPS at +31.4%, with operating margin around 16.9%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.5%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 23, 2026 | โ | +0.0% | +0.0% | โ |
2026 Mar 13, 2026 | โ | +0.0% | +0.0% | โ |
2025 Sep 8, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
MEDGF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
MEDGF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MEDGF and SPY.
Company Overview
Medacta Group S.A.
Other OTC
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Europe, North America, the Asia-Pacific, and internationally. It offers personalized kinematic models and 3D planning tools for use in hip, knee, shoulder, sports medicine, and spine procedures. The company was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.
- Leadership
- Francesco Siccardi
- IPO Date
- May 29, 2019
- Employees
- 1.9k
- Street Address
- Strada Regina, 34
- Mailing
- Castel San Pietro, 6874
- Region
- Castel San Pietro, CH
- Reporting Currency
- USD
- Investor Line
- 41 91 696 60 60
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 32.5
- EV/EBITDA
- 17.3
- Price/Sales
- 4.5
- Price/Book
- 6.8
Growth
- Revenue
- +16.5%
- EPS
- +31.4%
- Free Cash Flow
- +1119.0%
Profitability
- Gross Margin
- 67.1%
- Operating Margin
- 16.9%
- Net Margin
- 14.0%
- ROE
- 21.7%
- ROIC
- 11.9%
Balance Sheet
- Debt/Equity
- 0.58
- Current Ratio
- 2.08
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.